NGGT Biotechnology's investigational gene therapy NGGT001 demonstrated encouraging safety results in a Phase 1 trial for Bietti's crystalline dystrophy (BCD). The 12-month study showed no severe treatment-related adverse events, with preliminary efficacy data suggesting potential visual improvements in treated eyes.
The FDA cleared United Therapeutics' UKidney for US trials, a gene-edited porcine kidney product intended for end-stage renal disease via xenotransplant.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.